Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Small-Cell Lung Cancer Treatment Where is the Target?

Small-Cell Lung Cancer Treatment Where is the Target? Anjana JTO EDITORIAL Small-Cell Lung Cancer Treatment Small-Cell Lung Cancer Treatment Yang Where is the Target? James Chih-Hsin Yang, MD, PhD hemotherapy is very effective for the treatment of small-cell lung cancer (SCLC). CDespite the initial high response rates (RR), chemotherapy is rarely curative for extended stage (ED)-SCLC patients. In contrast to the high efficacy of first-line chemo - therapy, the RR and progression-free survival of second-line treatment are very modest. Patients refractory to first-line treatments (progression during treatment) and chemotherapy (disease progression within 3 months of last chemotherapy) often gain insignificant ben - efit from second-line treatments. Sensitive relapsed SCLC patients (progression 3 months after last chemotherapy) can be retreated with the first-line regimen or switched to second- line chemotherapy. However, they only represent a small proportion of patients and they generally become refractory to the treatment. Multiple chemotherapeutic regimens have been tested in ED SCLC as first-line treatment with similar good RR, progression-free sur - vival, and overall survival (OS) outcome. A systemic review of 5530 SCLC patients treated with platinum- versus nonplatinum-based regimens showed that there were no differences in RR and 12- or 24-month survival. Currently, cisplatin and etoposide (PE) remain the most popular standard http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Small-Cell Lung Cancer Treatment Where is the Target?

Journal of Thoracic Oncology , Volume 7 (9) – Sep 1, 2012

Loading next page...
 
/lp/wolters-kluwer-health/small-cell-lung-cancer-treatment-where-is-the-target-quest-Fh49bHbdrv

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2012 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e318265a7dc
pmid
22895135
Publisher site
See Article on Publisher Site

Abstract

Anjana JTO EDITORIAL Small-Cell Lung Cancer Treatment Small-Cell Lung Cancer Treatment Yang Where is the Target? James Chih-Hsin Yang, MD, PhD hemotherapy is very effective for the treatment of small-cell lung cancer (SCLC). CDespite the initial high response rates (RR), chemotherapy is rarely curative for extended stage (ED)-SCLC patients. In contrast to the high efficacy of first-line chemo - therapy, the RR and progression-free survival of second-line treatment are very modest. Patients refractory to first-line treatments (progression during treatment) and chemotherapy (disease progression within 3 months of last chemotherapy) often gain insignificant ben - efit from second-line treatments. Sensitive relapsed SCLC patients (progression 3 months after last chemotherapy) can be retreated with the first-line regimen or switched to second- line chemotherapy. However, they only represent a small proportion of patients and they generally become refractory to the treatment. Multiple chemotherapeutic regimens have been tested in ED SCLC as first-line treatment with similar good RR, progression-free sur - vival, and overall survival (OS) outcome. A systemic review of 5530 SCLC patients treated with platinum- versus nonplatinum-based regimens showed that there were no differences in RR and 12- or 24-month survival. Currently, cisplatin and etoposide (PE) remain the most popular standard

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Sep 1, 2012

References